Scholarlink

Introduction <p>Cabotegravir (CAB) is an integrase strand transfer inhibitor and the first long-acting injectable antiretroviral agent for human immunodeficiency virus (HIV), administered with rilpivirine. Because approval in Japan relied largely on overseas and international collaborative trials, domestic real-world evidence remains limited. This study evaluated the real-world safety and effectiveness of CAB in people living with HIV (PLHIV) in Japan.</p> Methods <p>This interim analysis (June 27, 2022 and June 17, 2025) was part of an ongoing post-marketing surveillance of Japanese PLHIV treated with CAB at institutions participating in the HIV-related Drugs Cooperative Survey. Safety was assessed by the incidence of adverse drug reactions (ADRs). Associations between ADR incidence and background characteristics were examined using Fisher’s exact and <i>χ</i><sup>2</sup> tests without multiplicity adjustment. Effectiveness was evaluated using virologic suppression assessed by log-transformed HIV RNA copies/mL and peripheral CD4<sup>+</sup> cell counts.</p> Results <p>A total of 121 and 117 participants were included in the safety and efficacy analysis sets, respectively; most were aged over 20&#xa0;years, and over 96% were male participants. Overall, 76 ADRs were reported in 45 participants (37.19%). The most frequent ADRs were injection site pain and musculoskeletal pain (12.40% each). Four serious ADRs that were not explicitly deemed unrelated to CAB by the reporting physicians occurred in 4 participants: hepatitis B reactivation, monkeypox, syphilis, and type 2 diabetes mellitus. Stratification analyses by participant characteristics revealed high ADR incidences among participants aged ≥ 30 to &lt; 40&#xa0;years (<i>p</i> = 0.038), without allergy (<i>p</i> = 0.016), and with comorbidities (<i>p</i> = 0.045). HIV RNA copies remained suppressed and CD4<sup>+</sup> cell counts were maintained at levels comparable to treatment initiation throughout follow-up.</p> Conclusion <p>This interim analysis indicates that CAB therapy is safe, with no new safety signals, and effective, as demonstrated by sustained virological suppression and stable CD4<sup>+</sup> cell counts. These findings are consistent with outcomes reported in overseas and international collaborative clinical studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-World Safety and Effectiveness of Cabotegravir in People Living with HIV: Interim Report of a Post-marketing Surveillance in Japan

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月16日

查看全文
  • Yoichiro Yoshikawa,
  • Takako Nagao,
  • Tomoko Matsukawa,
  • Yuko Maeno,
  • Akemi Sebata,
  • Miwako Suzuki,
  • Shiro Ibe,
  • Akiko Fukuda,
  • Dong Wang

摘要

Introduction

Cabotegravir (CAB) is an integrase strand transfer inhibitor and the first long-acting injectable antiretroviral agent for human immunodeficiency virus (HIV), administered with rilpivirine. Because approval in Japan relied largely on overseas and international collaborative trials, domestic real-world evidence remains limited. This study evaluated the real-world safety and effectiveness of CAB in people living with HIV (PLHIV) in Japan.

Methods

This interim analysis (June 27, 2022 and June 17, 2025) was part of an ongoing post-marketing surveillance of Japanese PLHIV treated with CAB at institutions participating in the HIV-related Drugs Cooperative Survey. Safety was assessed by the incidence of adverse drug reactions (ADRs). Associations between ADR incidence and background characteristics were examined using Fisher’s exact and χ2 tests without multiplicity adjustment. Effectiveness was evaluated using virologic suppression assessed by log-transformed HIV RNA copies/mL and peripheral CD4+ cell counts.

Results

A total of 121 and 117 participants were included in the safety and efficacy analysis sets, respectively; most were aged over 20 years, and over 96% were male participants. Overall, 76 ADRs were reported in 45 participants (37.19%). The most frequent ADRs were injection site pain and musculoskeletal pain (12.40% each). Four serious ADRs that were not explicitly deemed unrelated to CAB by the reporting physicians occurred in 4 participants: hepatitis B reactivation, monkeypox, syphilis, and type 2 diabetes mellitus. Stratification analyses by participant characteristics revealed high ADR incidences among participants aged ≥ 30 to < 40 years (p = 0.038), without allergy (p = 0.016), and with comorbidities (p = 0.045). HIV RNA copies remained suppressed and CD4+ cell counts were maintained at levels comparable to treatment initiation throughout follow-up.

Conclusion

This interim analysis indicates that CAB therapy is safe, with no new safety signals, and effective, as demonstrated by sustained virological suppression and stable CD4+ cell counts. These findings are consistent with outcomes reported in overseas and international collaborative clinical studies.